Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy

Abstract

Modafinil reduces somnolence and improves mood in patients with DM.

Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients

“…Although modafinil was effective in alleviating daytime sleepiness in several diseases, including multiple sclerosis, Parkinson's disease, and muscular dystrophy, 1,11,15,19 its effects on fatigue have been far less consistent. For example, fatigue symptoms did not change in Parkinson's disease patients.…”

Psychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation

“…However, due to very rare suspected cases of Stevens-Johnson syndrome during the ADHD clinical trials, the Food and Drug Administration failed to approve modafinil, to be marketed under the trade name Sparlon, for this indication (Cephalon, 2006;Food and Drug Administration, 2007). Modafinil was also effective at treating EDS in myotonic dystrophy (MacDonald et al, 2002;Talbot et al, 2003;Wintzen et al, 2007). All other therapeutic applications that were discussed in the review produced inconsistent findings or were inconclusive because of extremely small sample sizes (Kumar, 2008).…”

Serbian Validation of the Individualized Neuromuscular Quality of Life Questionnaire (INQoL) in Adults With Myotonic Dystrophy Type 1

“…However, there are very few studies that have specifi cally assessed QoL in DM1 [4,5]. Generic QoL questionnaires like SF-36 have been used in DM1 patients to assess the infl uence of some lesser recognized symptoms such as fatigue, daytime sleepiness and pain on QoL [6,7,8] and as a secondary outcome measure in clinical trials [9,10]. The use of generic questionnaires is acceptable in patients with neuromuscular disorders [3], but they can capture some issues superfl uous to those with muscle disorders and omit some important issues which may instead be captured by disease or symptom specifi c QoL questionnaire.…”